Clene Inc. (CLNN)
NASDAQ: CLNN · Real-Time Price · USD
5.03
-0.21 (-4.01%)
At close: Mar 3, 2026, 4:00 PM EST
5.11
+0.08 (1.59%)
After-hours: Mar 3, 2026, 4:10 PM EST
Clene Revenue
Clene had revenue of $15.00K in the quarter ending September 30, 2025, a decrease of -82.76%. This brings the company's revenue in the last twelve months to $214.00K, down -49.17% year-over-year. In the year 2024, Clene had annual revenue of $342.00K, down -47.71%.
Revenue (ttm)
$214.00K
Revenue Growth
-49.17%
P/S Ratio
288.40
Revenue / Employee
$2,816
Employees
76
Market Cap
58.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 342.00K | -312.00K | -47.71% |
| Dec 31, 2023 | 654.00K | 181.00K | 38.27% |
| Dec 31, 2022 | 473.00K | -250.00K | -34.58% |
| Dec 31, 2021 | 723.00K | 517.00K | 250.97% |
| Dec 31, 2020 | 206.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| The Hain Celestial Group | 1.51B |
| Farmer Bros. Co. | 337.72M |
| Bridgford Foods | 230.99M |
| Above Food Ingredients | 213.45M |
| LifeVantage | 210.05M |
| Laird Superfood | 48.15M |
| DDC Enterprise | 36.62M |
| BioHarvest Sciences | 32.72M |
CLNN News
- 7 days ago - Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts - GlobeNewsWire
- 12 days ago - Clene to Present at the Emerging Growth Conference - GlobeNewsWire
- 7 weeks ago - Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting - GlobeNewsWire
- 7 weeks ago - Clene Announces Registered Direct Offering of Over $28 Million - GlobeNewsWire
- 3 months ago - Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8® - GlobeNewsWire
- 3 months ago - Clene to Provide CNM-Au8® ALS Program Update - GlobeNewsWire
- 3 months ago - Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - GlobeNewsWire
- 3 months ago - Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights - GlobeNewsWire